Remimazolam is a recently developed ultra-short agonist acting at the benzodiazepine binding site of the gamma-aminobutyric acid (GABA)A receptor. Remimazolam has a combination of the hemodynamic stability of benzodiazepines and the advantages of propofol, such as rapid onset, short duration of action, and improved controllability. A recent study showed that the efficacy of two induction doses of remimazolam (6 and 12 mg/kg/h) as a sedative for general anesthesia was not inferior to propofol (2.0-2.5 mg/kg), and hemodynamically more stable. On the other hand, a study on the emergence time and quality between propofol and remimazolam showed inconsistent results. The purpose of this study is to compare remimazolam to propofol on the intraoperative hemodynamic changes and recovery profiles, when used in combination with remifentanil in elderly patients undergoing general anesthesia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
69
Patients will receive remimazolam at 6 mg/kg/hr by continuous infusion until loss of consciousness.
Patients will receive remimazolam at 12 mg/kg/hr by continuous infusion until loss of consciousness.
Patients will receive propofol at a target controlled infusion 4 µg/ml until loss of consciousness.
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
difference in the decreased mean arterial pressure
difference between baseline mean arterial pressure and lowest mean arterial pressure
Time frame: from the start of anesthetics (propofol or remimazolam) injection to the 5 minutes after extubation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.